Prothena Corporation PLC
NASDAQ:PRTA
Intrinsic Value
Prothena Corp. Plc is a clinical-stage neuroscience company. [ Read More ]
The intrinsic value of one PRTA stock under the Base Case scenario is 53.69 USD. Compared to the current market price of 20.56 USD, Prothena Corporation PLC is Undervalued by 62%.
Valuation Backtest
Prothena Corporation PLC
Run backtest to discover the historical profit from buying and selling PRTA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Prothena Corporation PLC
Current Assets | 639.3m |
Cash & Short-Term Investments | 618.8m |
Receivables | 5.2m |
Other Current Assets | 15.3m |
Non-Current Assets | 57.1m |
PP&E | 16m |
Other Non-Current Assets | 41.1m |
Current Liabilities | 56.9m |
Accounts Payable | 25.4m |
Accrued Liabilities | 29.1m |
Other Current Liabilities | 2.4m |
Non-Current Liabilities | 78.1m |
Other Non-Current Liabilities | 78.1m |
Earnings Waterfall
Prothena Corporation PLC
Revenue
|
91.4m
USD
|
Operating Expenses
|
-282.4m
USD
|
Operating Income
|
-191m
USD
|
Other Expenses
|
44m
USD
|
Net Income
|
-147m
USD
|
Free Cash Flow Analysis
Prothena Corporation PLC
PRTA Profitability Score
Profitability Due Diligence
Prothena Corporation PLC's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Prothena Corporation PLC's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
PRTA Solvency Score
Solvency Due Diligence
Prothena Corporation PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Prothena Corporation PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRTA Price Targets Summary
Prothena Corporation PLC
According to Wall Street analysts, the average 1-year price target for PRTA is 68.1 USD with a low forecast of 34.34 USD and a high forecast of 98.7 USD.
Ownership
PRTA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PRTA Price
Prothena Corporation PLC
Average Annual Return | 82.94% |
Standard Deviation of Annual Returns | 147.27% |
Max Drawdown | -74% |
Market Capitalization | 1.1B USD |
Shares Outstanding | 53 720 500 |
Percentage of Shares Shorted | 18.98% |
PRTA News
Last Important Events
Prothena Corporation PLC
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Prothena Corporation PLC
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
Contact
IPO
Employees
Officers
The intrinsic value of one PRTA stock under the Base Case scenario is 53.69 USD.
Compared to the current market price of 20.56 USD, Prothena Corporation PLC is Undervalued by 62%.